You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金城醫藥(300233.SZ):金方恆健投資的惠和生物三特異性抗CC312IND申請獲美國FDA默示許可
格隆匯 05-16 21:34

格隆匯5月16日丨金城醫藥(300233.SZ)公佈,公司於近日收到金方恆健的通知,其投資的惠和生物三特異性抗CC312IND申請獲得美國FDA默示許可,是國內首個,也是全球第三個基於CD28共刺激信號的三特異性抗體進入臨牀研發階段。

根據金方恆健簽署的投資協議,在優先產品受讓及產業化權利方面,金方恆健關聯方金城醫藥(300233)有權在同等條件下優先受讓;如果惠和生物為研發產品選擇產業化基地,金方恆健有權要求在同等條件下,優先在其推薦的產業園進行產業化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account